37,787 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Bought by Quantinno Capital Management LP

Posted by Brian Himes on Aug 19th, 2026

Quantinno Capital Management LP bought a new position in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 37,787 shares of the company’s stock, valued at approximately $684,000.

Several other hedge funds have also modified their holdings of the stock. Suvretta Capital Management LLC boosted its position in shares of Legend Biotech by 73.1% in the 4th quarter. Suvretta Capital Management LLC now owns 6,608,629 shares of the company’s stock valued at $143,672,000 after purchasing an additional 2,790,620 shares during the period. Westfield Capital Management Co. LP raised its holdings in Legend Biotech by 1.2% during the 4th quarter. Westfield Capital Management Co. LP now owns 6,164,677 shares of the company’s stock worth $134,020,000 after buying an additional 70,191 shares during the period. Goldman Sachs Group Inc. raised its holdings in Legend Biotech by 120.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,174,535 shares of the company’s stock worth $47,274,000 after buying an additional 1,188,449 shares during the period. Alliancebernstein L.P. lifted its stake in Legend Biotech by 4.6% during the third quarter. Alliancebernstein L.P. now owns 1,632,967 shares of the company’s stock valued at $53,251,000 after buying an additional 72,371 shares in the last quarter. Finally, State Street Corp lifted its stake in Legend Biotech by 31.0% during the fourth quarter. State Street Corp now owns 1,516,368 shares of the company’s stock valued at $32,966,000 after buying an additional 359,246 shares in the last quarter. 70.89% of the stock is owned by hedge funds and other institutional investors.

Legend Biotech Trading Up 6.2%

LEGN stock opened at $21.92 on Wednesday. Legend Biotech Corporation Sponsored ADR has a 1 year low of $16.24 and a 1 year high of $37.50. The company has a fifty day simple moving average of $25.41 and a 200 day simple moving average of $23.22. The firm has a market cap of $4.07 billion, a PE ratio of -87.68 and a beta of 0.37.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.02. The company had revenue of $387.50 million during the quarter, compared to the consensus estimate of $355.96 million. Legend Biotech had a negative return on equity of 8.71% and a negative net margin of 7.21%.The firm’s revenue was up 51.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.03 EPS. As a group, analysts forecast that Legend Biotech Corporation Sponsored ADR will post 0.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Legend Biotech news, CEO Ying Huang sold 5,566 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $14.78, for a total transaction of $82,265.48. Following the completion of the sale, the chief executive officer owned 241,872 shares of the company’s stock, valued at $3,574,868.16. This represents a 2.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.02% of the company’s stock.

Analyst Ratings Changes

LEGN has been the topic of several analyst reports. Benchmark reissued a “buy” rating on shares of Legend Biotech in a research report on Tuesday, July 28th. JPMorgan Chase & Co. initiated coverage on shares of Legend Biotech in a research report on Monday, July 13th. They issued a “neutral” rating and a $35.00 price target for the company. Oppenheimer lowered shares of Legend Biotech from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $75.00 to $40.00 in a research note on Wednesday, August 12th. Morgan Stanley lifted their price objective on shares of Legend Biotech from $48.00 to $49.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Finally, Barclays cut their target price on shares of Legend Biotech from $80.00 to $78.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 12th. Eight investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Legend Biotech has a consensus rating of “Hold” and an average price target of $52.29.

View Our Latest Report on LEGN

Legend Biotech Profile

(Free Report)

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.